{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:34:08Z","timestamp":1790847248727,"version":"4.1.0"},"reference-count":32,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,3,30]],"date-time":"2015-03-30T00:00:00Z","timestamp":1427673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2015,7]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Myelofibrosis is characterized by splenomegaly and debilitating constitutional symptoms that negatively impact patients\u2019 quality of life.\n                    <jats:styled-content style=\"fixed-case\">ROBUST<\/jats:styled-content>\n                    , a\n                    <jats:styled-content style=\"fixed-case\">UK<\/jats:styled-content>\n                    , open\u2010label, phase\n                    <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content>\n                    study, evaluated the safety and efficacy of ruxolitinib in patients with myelofibrosis (\n                    <jats:italic>N<\/jats:italic>\n                    \u00a0=\u00a048), including intermediate\u20101 risk patients. The primary composite endpoint was the proportion of patients achieving treatment success [\u226550% reduction in palpable spleen length and\/or a \u226550% decrease in Myelofibrosis Symptom Assessment Form Total Symptom Score (\n                    <jats:styled-content style=\"fixed-case\">MF<\/jats:styled-content>\n                    \u2010\n                    <jats:styled-content style=\"fixed-case\">SAF TSS<\/jats:styled-content>\n                    )] at 48\u00a0weeks. This was the first time that efficacy of ruxolitinib in myelofibrosis has been evaluated based on these criteria and the first time the\n                    <jats:styled-content style=\"fixed-case\">MF<\/jats:styled-content>\n                    \u2010\n                    <jats:styled-content style=\"fixed-case\">SAF<\/jats:styled-content>\n                    was used in a population of patients solely from the United Kingdom. Overall, 50% of patients and 57% of intermediate\u20101 risk patients, achieved treatment success; reductions in spleen length and symptoms were observed in all risk groups. The majority of patients (66\u00b77%) experienced \u226550% reductions from baseline in spleen length at any time. Improvements in\n                    <jats:styled-content style=\"fixed-case\">MF<\/jats:styled-content>\n                    \u2010\n                    <jats:styled-content style=\"fixed-case\">SAF TSS<\/jats:styled-content>\n                    were seen in 80\u00b70%, 72\u00b77%, and 72\u00b72% of intermediate\u20101, intermediate\u20102, and high\u2010risk patients, respectively. Consistent with other studies of ruxolitinib, the most common haematological adverse events were anaemia and thrombocytopenia. Results indicate that most patients with myelofibrosis, including intermediate\u20101 risk patients, may benefit from ruxolitinib treatment.\n                  <\/jats:p>","DOI":"10.1111\/bjh.13379","type":"journal-article","created":{"date-parts":[[2015,3,30]],"date-time":"2015-03-30T04:57:29Z","timestamp":1427691449000},"page":"29-39","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["Response to ruxolitinib in patients with intermediate\u20101\u2013, intermediate\u20102\u2013, and high\u2010risk myelofibrosis: results of the\n                    <scp>UK ROBUST<\/scp>\n                    Trial"],"prefix":"10.1111","volume":"170","author":[{"given":"Adam J.","family":"Mead","sequence":"first","affiliation":[{"name":"MRC Weatherall Institute of Molecular Medicine University of Oxford Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragana","family":"Milojkovic","sequence":"additional","affiliation":[{"name":"Imperial College Healthcare NHS Trust Hammersmith Hospital London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Knapper","sequence":"additional","affiliation":[{"name":"Department of Haematology Cardiff University, Heath Park Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamta","family":"Garg","sequence":"additional","affiliation":[{"name":"Leicester Royal Infirmary Leicester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Chacko","sequence":"additional","affiliation":[{"name":"The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust Bournemouth UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Farquharson","sequence":"additional","affiliation":[{"name":"Department of Haematology Western General Hospital Edinburgh UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Haematology Manchester Royal Infirmary Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahra","family":"Ali","sequence":"additional","affiliation":[{"name":"Hull and East Yorkshire Hospitals NHS Trust Hull UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Clark","sequence":"additional","affiliation":[{"name":"Department of Haematology Royal Liverpool University Hospital Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Andrews","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals UK Frimley UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meryem Ktiouet","family":"Dawson","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals UK Frimley UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Harrison","sequence":"additional","affiliation":[{"name":"Guy's and St. Thomas\u2019 NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,3,30]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.60.041707.160528"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71142-9"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00435221"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-170449"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-485888"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03546"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311347"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051113"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.12.002"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22365"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.01.035"},{"key":"e_1_2_8_16_1","article-title":"Results using the modified myelofibrosis symptom assessment form (MFSAF v2.0) in COMFORT\u2010I: a randomized, double\u2010blind, phase 3 trial of JAK1\/2 inhibitor ruxolitinib vs placebo in myelofibrosis","volume":"96","author":"Mesa R.A.","year":"2011","journal-title":"Haematologica"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.04.017"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.4489"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312542"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030270"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065202"},{"key":"e_1_2_8_22_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow S.H.","year":"2008"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.94"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.710"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-009746"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23384"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-488098"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209262"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1086\/520514"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_2_8_31_1","first-page":"396","article-title":"Long\u2010term outcomes of ruxolitinib therapy in patients with myelofibrosis: 3\u2010year update from COMFORT\u2010I","volume":"122","author":"Verstovsek S.","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-004-7713-0"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1302135"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.13379","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13379","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T06:02:52Z","timestamp":1696312972000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.13379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,30]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.1111\/bjh.13379"],"URL":"https:\/\/doi.org\/10.1111\/bjh.13379","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,30]]},"assertion":[{"value":"2014-12-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-01-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-03-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}